DE60022230D1 - Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv - Google Patents

Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv

Info

Publication number
DE60022230D1
DE60022230D1 DE60022230T DE60022230T DE60022230D1 DE 60022230 D1 DE60022230 D1 DE 60022230D1 DE 60022230 T DE60022230 T DE 60022230T DE 60022230 T DE60022230 T DE 60022230T DE 60022230 D1 DE60022230 D1 DE 60022230D1
Authority
DE
Germany
Prior art keywords
clarithromycin
preparation
polymorph
polymorphen
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60022230T
Other languages
English (en)
Other versions
DE60022230T2 (de
Inventor
Ilya Avrutov
Igor Lifshitz
Ronen Borochovitz
Basem Masarwa
Edi Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of DE60022230D1 publication Critical patent/DE60022230D1/de
Publication of DE60022230T2 publication Critical patent/DE60022230T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicinal Preparation (AREA)
DE60022230T 1999-12-16 2000-12-15 Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv Expired - Fee Related DE60022230T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17122199P 1999-12-16 1999-12-16
US171221P 1999-12-16
US17183999P 1999-12-22 1999-12-22
US171839P 1999-12-22
PCT/US2000/033845 WO2001044262A1 (en) 1999-12-16 2000-12-15 Processes for preparing clarithromycin polymorphs and novel polymorph iv

Publications (2)

Publication Number Publication Date
DE60022230D1 true DE60022230D1 (de) 2005-09-29
DE60022230T2 DE60022230T2 (de) 2006-01-26

Family

ID=26866853

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60022230T Expired - Fee Related DE60022230T2 (de) 1999-12-16 2000-12-15 Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv

Country Status (20)

Country Link
US (2) US6599884B2 (de)
EP (1) EP1254146B1 (de)
JP (1) JP2003516999A (de)
KR (1) KR20020070991A (de)
CN (2) CN1666991A (de)
AT (1) ATE302786T1 (de)
AU (1) AU783055B2 (de)
CA (1) CA2395555A1 (de)
CZ (1) CZ20021999A3 (de)
DE (1) DE60022230T2 (de)
ES (1) ES2244491T3 (de)
HR (1) HRP20020522A2 (de)
HU (1) HUP0204091A3 (de)
IL (1) IL150227A0 (de)
PL (1) PL364880A1 (de)
PT (1) PT1254146E (de)
RU (1) RU2002116232A (de)
SK (1) SK8322002A3 (de)
WO (1) WO2001044262A1 (de)
YU (1) YU45602A (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1280535T1 (de) * 2000-01-11 2005-08-31 Teva Pharma
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
HUP0302466A2 (hu) * 2000-02-29 2003-11-28 Teva Pharmaceutical Industries Ltd. Eljárások clarithromycin, clarithromycin intermedier, gyakorlatilag oximmentes clarithromycin és ezt tartalmazó gyógyszerkészítmény előállítására
MXPA02009587A (es) * 2000-03-28 2003-05-14 Biochemie Gmbh Particulas granuladas con sabor enmascarado.
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2535780A1 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
EP2030613A1 (de) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法
RU2021125455A (ru) 2013-11-15 2021-10-05 Экебиа Терапьютикс, Инк. Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954572A (de) * 1972-09-29 1974-05-27
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4660386A (en) * 1985-09-18 1987-04-28 Hansen John C Diagnostic system for detecting faulty sensors in liquid chiller air conditioning system
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5274065A (en) * 1990-10-18 1993-12-28 Technical Development Associates Polyorganosiloxane-polyamide block copolymers
JPH0665080A (ja) * 1992-03-10 1994-03-08 Godo Shiyusei Kk α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
ES2173057T3 (es) * 1996-07-29 2004-11-16 Abbott Laboratories Preparacion de la forma ii cristalina de claritromicina.
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
AU4942800A (en) * 1999-06-11 2001-01-02 Ranbaxy Laboratories Limited Novel amorphous form of clarithromycin
SI1280535T1 (de) * 2000-01-11 2005-08-31 Teva Pharma
HUP0302466A2 (hu) * 2000-02-29 2003-11-28 Teva Pharmaceutical Industries Ltd. Eljárások clarithromycin, clarithromycin intermedier, gyakorlatilag oximmentes clarithromycin és ezt tartalmazó gyógyszerkészítmény előállítására

Also Published As

Publication number Publication date
US6599884B2 (en) 2003-07-29
PT1254146E (pt) 2005-10-31
CN1666991A (zh) 2005-09-14
ES2244491T3 (es) 2005-12-16
CN1434829A (zh) 2003-08-06
US20040058879A1 (en) 2004-03-25
EP1254146A4 (de) 2003-04-16
CZ20021999A3 (cs) 2003-02-12
AU783055B2 (en) 2005-09-22
WO2001044262A1 (en) 2001-06-21
CA2395555A1 (en) 2001-06-21
EP1254146A1 (de) 2002-11-06
HRP20020522A2 (en) 2004-12-31
AU2431101A (en) 2001-06-25
DE60022230T2 (de) 2006-01-26
RU2002116232A (ru) 2004-01-10
ATE302786T1 (de) 2005-09-15
KR20020070991A (ko) 2002-09-11
PL364880A1 (en) 2004-12-27
HUP0204091A3 (en) 2003-05-28
HUP0204091A2 (hu) 2003-04-28
YU45602A (sh) 2005-06-10
IL150227A0 (en) 2002-12-01
SK8322002A3 (en) 2003-02-04
EP1254146B1 (de) 2005-08-24
CN1217951C (zh) 2005-09-07
US20020026038A1 (en) 2002-02-28
JP2003516999A (ja) 2003-05-20

Similar Documents

Publication Publication Date Title
DE60022230D1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
AP1709A (en) Ethanolate of azithromycin, process for manufacure, and pharmaceutical compositions thereof.
PL345215A1 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
PT915898E (pt) Forma i cristalina de claritromicina
DE69104991T2 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
MA27080A1 (fr) Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
ATE534656T1 (de) Neue oligosaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EP0992509A3 (de) Neue Makrolidderivate
NO20032371L (no) Makrolidsolvater
AP9801377A0 (en) Tricyclic erythromycin derivatives.
WO2005055943A3 (en) Vinorelbine derivatives
DE602004011921D1 (de) Verfahren zur herstellung von (4-hydroxy-6-oxo-tetrahydropyran-2-yl) acetonitril und dessen derivaten
AP9801235A0 (en) Erythromycin derivatives.
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
NO20031137L (no) Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av kiraleforbindelser under betingelsene for en 1,4-Michael-addisjon.Oppfinnelsen angårogså de tilsvarende forbindelser
EP1176149A4 (de) Derivate der gymnemischen säure, verfahren zu ihrer herstellung und ihre verwendung als medikamente
UA74406C2 (uk) Полісахаридна сполука з імуностимулювальною активністю, спосіб її одержання, застосування та фармацевтичний препарат на її основі
MXPA03003466A (es) Derivados de piranosido.
IL150979A0 (en) 9-alkylamino-1-nitroacridine derivatives
DK1235850T3 (da) Umættede 14,15-cyclopropano-androstaner, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee